Notable comorbidities or histories of dyslipidemia, hyperlipidemia, or hepatobiliary disorders were found in all patients with lipase >3 × ULN.
Three notable comorbidities not known to be associated with antiviral treatment or disease were benign neoplasms (24.3%), genitourinary symptoms & ill-defined conditions (14.8%), and viral infections (13.8%).
We excluded those who died early despite initial resuscitation attempts and those who could not be stabilized, and patients with notable comorbidities (like cirrhosis, arteriopathy, or impaired cardiac function) were also excluded.
Because short term mortality is likely to be closely related to the severity and progression of myocardial infarction, it is notable that comorbidity had a substantial influence on 30 day mortality.
TIGER patients hospitalized with a primary diagnosis of psychiatric disorder, epilepsy, or non-epilepsy medical conditions had notable differences in neurological and psychiatric comorbidity.
High rates of negative emotional states regardless of the ongoing OnabotA therapy in our patients seems notable given the impact of psychiatric comorbidities on disease prognosis, treatment, and clinical outcomes and higher prevalence of severe headache-related disability, headache impact and poor quality of life in migraineurs with than without psychiatric comorbidities [11, 13, 64].
Similarly, the magnitude of the association between "both anxiety and depression" and HRQoL (Total, Activity and Impact domains) was stronger in COPD patients with two or more Charlson comorbidities than in patients with one comorbidity; this association was especially notable in the Impact domain.
Some differences in factors associated with all-cause mortality (Table 6) compared to cause-specific mortality were evident for each racial/ethnic group, but the most notable difference was the considerably higher impact of comorbidity on mortality, with patients with one or more comorbid conditions having 34% (Hispanics) to 73% (Filipinos) higher mortality than patients without any comorbidities.
There is significant heterogeneity in clinical phenotype and many potential comorbidities such as attention problems, impulsivity, notable responses to sensory input, oppositional behaviors, depression, feeding and sleeping differences, fears or anxieties, cognitive delays, and epilepsy and other health problems (APA, 2013; Bryson et al., 2008; Lord and Spence, 2006).
Additionally, robust propensity score modeling was used to help minimize potential confounding, and competing risk methods were used given that competing risks are of notable concern due to the age and prevalence of comorbidities in this particular patient population.
A notable feature of this study is the high degree of comorbidity found between adult psychotic-like experiences and GHQ scores.
